Company intelligence / Profile preview

Pentracor

Hennigsdorf, Brandenburg, Germanypentracor.de ↗

Ownership: Private
Employees: ~8
Development stage: Other

Overview

The company’s main product, PentraSorb CRP, enables extracorporeal removal of C-reactive protein to reduce tissue damage after acute myocardial infarction and potentially other inflammatory conditions. The therapy has been used clinically in Europe and was being positioned for broader indications including COVID‑19. Clinical results suggest improved outcomes by reducing inflammation-driven tissue injury.

Therapeutic areas: Infectious DiseasesImmunologyCardiovascular
Modalities: Device (extracorporeal adsorber)Non-pharmacological therapy (CRP apheresis)
Industry: Therapeutic Medical Devices

Partnerships

High-Tech Grunderfonds investor partnership

Beyond the preview

Go deeper on Pentracor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pentracor.

Explore the full profile